Table 2.

Objective response rate

Variable	All	EV after avelumab group	EV after pembrolizumab group	p-value
No. of patients	100	21	79
Best response assessed using RECIST criteria				0.11
CR	5 (5%)	3 (14.2%)	2 (2.5%)
PR	46 (46%)	11 (52.3%)	35 (44.3%)
SD	23 (23%)	4 (19%)	19 (24%)
PD	26 (26%)	3 (14.2%)	23 (29.1%)
ORR	51 (51%)	14 (66.6%)	37 (46.8%)	0.14
DCR	74 (74%)	18 (85.7%)	56 (70.8%)	0.26

DCR = CR + PR + SD

ORR = CR + PR

EV enfortumab vedotin; CR complete response; PR partial response; SD, table disease; PD progressive disease; ORR objective response rate; DCR disease control rate